An in-house reverse-genetics generated H5N9 inactivated vaccine (SEP-22- N9) was evaluated for its vaccine efficacy in ...
Ella's combination of performance and workflow brings your immunoassays to the next level. In just 90 minutes you get highly reproducible validated assay data with no manual steps. The assay ...
NfL was assessed using the ultrasensitive Simoa and microfluidic Ella platforms and with Lumipulse and Elecsys assays, ...
HealthDay on MSN14d
Four Immunoassays for Neurofilament Light Chain Show Consistent Performance in ALSNfL was assessed using the ultrasensitive Simoa and microfluidic Ella platforms and with Lumipulse and Elecsys assays, recently set up on clinical-grade platforms. Serum GFAP and pTau181 were also ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Immune responses are measured by hemagglutination inhibition (HAI), virus microneutralization (MN) and neuraminidase enzyme-linked lectin assays (ELLA). In February, the Company announced the ...
StudyFinds on MSN10d
Breakthrough blood test could transform ALS diagnosis, careFind out about the new ALS blood test that offers accurate diagnosis and could replace traditional invasive testing methods.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback